The economics that support access to psychedelic therapies.
We are a network of health economists and health services researchers producing the objective evidence that insurers, policymakers, and health systems need to make psychedelic therapies accessible to everyone who can benefit.
THE ACCESS GAP
Evidence is the bridge between promise and access.
A new generation of psychedelic therapies has emerged to manage conditions like depression, PTSD, and addiction. But efficacy without economics is a finding, not a treatment. CEP builds the evidence that decision-makers need to expand access to psychedelic-assisted therapies, closing the gap between trials and the people that could benefit from them.
Psychedelic therapies show promise for depression, PTSD, and substance use disorders.
01
Without economic validation, there is no insurance coverage.
02
Without coverage, access is limited to those who can pay out of pocket.
03
Featured Projects
-
ORCHID
Oregon–Colorado Regulated Psychedelic Care: Healthcare Impacts & Decisions.
ORCHID generates real-world evidence linking state-regulated psilocybin services to changes in healthcare costs, utilization, and outcomes. The evidence insurers, employers, and policymakers need before coverage decisions become possible.
-
Consensus well-being measures
Well-Being as a Co-Primary Endpoint in Psychedelic Trials.
CEP is advancing a standardized way to measure the broader improvements psychedelic therapies may produce beyond symptom reduction. The goal is a validated instrument the field can use consistently across trials, giving researchers and payers a clearer basis for comparing outcomes and assigning value.
Current Projects
-
Cost-effectiveness of ibogaine for opioid withdrawal
Medicaid-focused cost-effectiveness analysis comparing ibogaine-assisted therapy with standard medication-assisted treatment for opioid use disorder
-
Ketamine IVPE
The study examines the cost-effectiveness of ketamine therapy for major depressive disorder within an IVPE trial.
-
New Mexico psilocybin program
How group-based psilocybin care could be staffed, delivered, and costed within New Mexico’s state program, with relevance for Medicaid populations and other states.
-
MDMA-assisted therapy in Lebanon
The feasibility, delivery costs, and potential health and economic impact of MDMA-assisted therapy for PTSD in Lebanon.
-
Regional expansion
Explores implementation readiness for psychedelic-assisted therapies across the Middle East.
-
PATPath
Potential eligibility and demand for psilocybin-assisted therapy across different populations and settings.
-
Demand for MDMA-assisted therapy
Estimates U.S. eligibility and likely demand for MDMA-assisted therapy.
-
Persistent Health Outcomes Associated with Naturalistic MDMA Use: A Systematic Review of Human Studies, 1999–2025
Long-term health outcomes after naturalistic MDMA use and the strength of the evidence behind reported risks.
Who We Serve
Private Payers, Medicaid &
Medicare
Cost-effectiveness and budget-impact evidence for coverage decisions.
Policymakers, Regulators & Government
Independent analysis on the fiscal and access implications of psychedelic policy.
Researchers
Shared methods and collaborative study design.
Providers
Delivery-model economics for service planning.
Funders
Rigorous, fundable research priorities.
Ultimately, we serve the public
in the US and around the world, by helping proven therapies reach the people who need them.